-
article Mahul-Mellier AL, van den Heuvel L, Teixeira M, Boussouf MLN, Oudinot G, Thonet A, Speri D, Jasiqi Y, Ulrich C, Sheta R, Idi W, Croisier M, Clerc-Rosset S, Blanc J, Knott G, Oueslati A, Lashuel HA
Modeling Parkinsons pathology in human iPSC dopaminergic neurons uncovers key mechanisms of Lewy body formation and heterogeneity
Sci Adv 12 (28), 2026.
-
article Martínez-Drudis L, Sheta R, Musiol D, Teixeira M, Oueslati A
The emerging role of polo-like kinase 2 in Alzheimers disease
Exp Neurol 403 2026.
-
article Rodriguez-Aller R, Romero-Quineche B, Morissette M, Sheta R, Di Paolo T, Saghatelyan A, Oueslati A
Optogenetic-induced α-synuclein accumulation reveals early synaptic dysfunction in experimental models of Parkinsons disease
NPJ Parkinsons Dis 11 (1), 2025.
-
article Idi W, Sheta R, Oueslati A
Interplay between lipid droplets and alpha-synuclein: implication in Parkinsons disease pathogenesis
Front Mol Neurosci 18 2025.
-
article Teixeira M, Musiol D, Lambert JP, Oueslati A
Protocol for dissecting the aggregation-prone protein interactome with optogenetic-induced aggregation and biotin labeling proximity assay
STAR Protoc 7 (1), 2026.
-
article Lepinay E, Saint-Pierre M, Teixeira M, Snapyan M, Oueslati A, Parent M, Alpaugh M, Cicchetti F
The impact of tau deletion on Huntingtons disease: an in vivo perspective
Mol Ther 34 (3), 2026.
-
article Teixeira M, Sheta R, Musiol D, Ranjakasoa V, Loehr J, Lambert JP, Oueslati A
Combining light-induced aggregation and biotin proximity labeling implicates endolysosomal proteins in early α-synuclein oligomerization
iScience 28 (7), 2025.
-
article Bartl S, Xie Y, Potluri N, Kesineni R, Hencak K, Cengio LD, Balazs K, Oueslati A, Parth M, Salhat N, Siddu A, Smrzka O, Cicchetti F, Straffler G, Hayden MR, Southwell AL
Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease
Neurobiol Dis 190 2024.
-
article Sheta R, Bérard M, Musiol D, Martínez-Drudis L, Oueslati A
Behavioral analysis of motor and non-motor impairment in rodent models of Parkinson’s disease
Front Aging Neurosci 16 2024.
-
article Bartl S, Xie Y, Potluri N, Kesineni R, Hencak K, Cengio LD, Balazs K, Oueslati A, Parth M, Salhat N, Siddu A, Smrzka O, Cicchetti F, Staffler G, Hayden MR, Southwell AL
Corrigendum to “Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease” [Neurobiology of Disease, 2024 Jan:190:106376]
Neurobiol Dis 193 2024.
-
article Martínez-Drudis L, Bérard M, Musiol D, Rivest S, Oueslati A
Pharmacological inhibition of PLK2 kinase activity mitigates cognitive decline but aggravates APP pathology in a sex-dependent manner in APP/PS1 mouse model of Alzheimer’s disease
Heliyon 10 (20), 2024.
-
article Bérard M, Martínez-Drudis L, Sheta R, El-Agnaf OMA, Oueslati A
Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson’s disease in rodent brains
Mol Neurodegener 18 (1), 2023.
The Charter of the French Language and its regulations govern the consultation of English language content.
